NEWARK, N.J., June 18, 2012 /PRNewswire-Asia-FirstCall/ -- The
Board of Directors (the "Board") of American Oriental
Bioengineering, Inc. , (the "Company", or "we" ), by unanimous
written consent appointed Cosimo J.
Patti, an independent director of the Board since 2004, as
the Chairman of the audit committee of the Board.
Mr. Patti has no family relationships with any of the executive
officers or directors of the Company. There have been no
transactions in the past two years to which the Company or any of
its subsidiaries was, or is to be a party, in which Mr. Patti had
or will have a direct or indirect material interest.
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical
company dedicated to improving health through the development,
manufacture and commercialization of a broad range of prescription
and over the counter products.
Safe Harbor Statement
Statements made in this press release are forward-looking and
are made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve risks
and uncertainties that may cause actual results to differ
materially from those set forth in these statements. The
economic, competitive, governmental, technological and other
factors identified in the Company's filings with the Securities and
Exchange Commission may cause actual results or events to differ
materially from those described in the forward looking statements
in this press release. The Company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or
otherwise.
SOURCE American Oriental Bioengineering, Inc.